Friday, July 10, 2026

Patent intelligence · US

US 12213985

Oral cannabinoid formulations

granted A61KA61K31/05A61K31/658A61K47/10
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 19
Applicant portfolio 89
Patent details — US 12213985
Jurisdiction
US
Status
granted
Grant date
Feb 4, 2025
Expiration
Jan 30, 2045
Claims
27
CPC classes
A61K, A61K31/05, A61K31/658, A61K47/10
View on Google Patents ↗

Quick answer

US 12213985 (Oral cannabinoid formulations) is held by JAZZ PHARMACEUTICALS RESEARCH UK LIMITED. Status: granted. Granted Feb 4, 2025. Expires Jan 30, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
27
CPC classes
A61K, A61K31/05, A61K31/658, A61K47/10, A61K47/14, A61K47/183

More from JAZZ PHARMACEUTICALS RESEARCH UK LIMITED

Related pharmaceutical patents in our USPTO index.

  1. US 12427160

    Use of cannabinoids in the treatment of epilepsy

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Expires Sep 25, 2045

    granted
  2. US 12403136

    Cannabinoid derivatives as pharmaceutically active compounds and methods of preparation thereof

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Expires Aug 28, 2045

    granted
  3. US 12396963

    Cannabidiol-type cannabinoid compound

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Expires Aug 21, 2045

    granted
  4. US 12383512

    Cannabidiol-type cannabinoid compound

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Expires Aug 7, 2045

    granted
  5. US 12383567

    Use of cannabinoids in the treatment of epilepsy

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Expires Aug 7, 2045

    granted
  6. US 12364670

    Cannabidiol-type cannabinoid compound

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Expires Jul 17, 2045

    granted
  7. US 12357586

    Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Expires Jul 10, 2045

    granted
  8. US 12350253

    Use of cannabinoids in the treatment of dyskinesia associated with parkinson's disease

    JAZZ PHARMACEUTICALS RESEARCH UK LIMITED · Expires Jul 3, 2045

    granted

Frequently asked questions

What is US patent 12213985?

US 12213985 (Oral cannabinoid formulations) is held by JAZZ PHARMACEUTICALS RESEARCH UK LIMITED. Status: granted. Granted Feb 4, 2025. Expires Jan 30, 2045 (19 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 12213985?

JAZZ PHARMACEUTICALS RESEARCH UK LIMITED is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 89 pharmaceutical patents for this assignee.

When does US 12213985 expire?

Our index shows an expiration date of Jan 30, 2045 (19 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.